Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Cash from Financing Activities (2018 - 2025)

10x Genomics' Cash from Financing Activities history spans 8 years, with the latest figure at $2.2 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 50.37% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $6.8 million, down 37.67%, while the annual FY2025 figure was $6.8 million, 37.67% down from the prior year.
  • Cash from Financing Activities for Q4 2025 was $2.2 million at 10x Genomics, up from $617000.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $16.2 million in Q2 2021 and bottomed at -$3.4 million in Q1 2023.
  • The 5-year median for Cash from Financing Activities is $3.9 million (2023), against an average of $4.1 million.
  • The largest annual shift saw Cash from Financing Activities tumbled 241.25% in 2023 before it surged 295.51% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $8.9 million in 2021, then crashed by 43.83% to $5.0 million in 2022, then grew by 12.24% to $5.6 million in 2023, then decreased by 19.53% to $4.5 million in 2024, then plummeted by 50.37% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for TXG's Cash from Financing Activities are $2.2 million (Q4 2025), $617000.0 (Q3 2025), and $3.5 million (Q2 2025).